Quantum Computing, Inc. Announces Collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute To Support Research Using Dirac-3 Systems

Rhea-AI Summary

Quantum Computing Inc. (QUBT) has announced a strategic collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI) to advance computational biomedicine research. Through this partnership, QCi will provide Sanders TDI with cloud-based access to its Dirac-3 Entropy Quantum Computing Machine, which operates at room temperature and low power.

Sanders TDI, a New York City-based non-profit drug discovery institute comprising Kettering Cancer Center, The Rockefeller University, and Memorial Sloan Weill Cornell Medicine, will utilize QCi's quantum computation technology for experimental work. The collaboration aims to advance computational chemistry research through quantum-enabled applications, focusing on biomolecular modeling and proof of concept calculations.

The partnership demonstrates QCi's commitment to making quantum machines accessible and affordable while showcasing real-world applications of quantum computing technology.

Positive

• Strategic collaboration with prestigious medical research institutions
• Expansion into biomedical and pharmaceutical research applications
• Demonstration of real-world commercial applications for QCi's technology

Negative

• None.

Insights

Quantum Technology Analyst

This collaboration marks a strategic pivot into the biomedical research sector for QCi's Dirac-3 quantum computing platform. The partnership with Sanders TDI, which brings together three prestigious medical institutions, positions QCi's room-temperature quantum systems for real-world applications in drug discovery and computational biomedicine. The key technical advantage of Dirac-3's ability to operate at room temperature and low power significantly reduces operational costs compared to traditional quantum computers requiring cryogenic cooling.

The collaboration's focus on computational chemistry and biomolecular modeling represents a high-value market opportunity. Drug discovery typically costs pharmaceutical companies $1-2 billion per successful drug, with computational modeling being a critical cost-saving tool. QCi's quantum systems could potentially accelerate this process, reducing both time and costs in the drug development pipeline.

For investors, this partnership validates QCi's technology in a practical, revenue-generating application while opening doors to the lucrative pharmaceutical research market. However, the announcement lacks specific financial terms or timeline commitments, making immediate revenue impact uncertain.

Biotech Research Analyst

The integration of QCi's quantum computing capabilities into Sanders TDI's drug discovery platform represents a significant technological advancement in computational biomedicine. Traditional molecular modeling faces limitations with complex protein interactions and drug binding simulations. Quantum computing could potentially solve these computational bottlenecks, particularly in:

• Protein folding predictions
• Drug-target interaction modeling
• Optimization of lead compounds

The collaboration with Sanders TDI, which combines the research power of three leading medical institutions, provides QCi with valuable validation in the pharmaceutical research space. However, quantum computing in drug discovery remains largely experimental and successful implementation will require significant development and validation work. The lack of specific success metrics or development timelines suggests this is still in early exploratory phases.

HOBOKEN, N.J., Jan. 15, 2025 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today announced a collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute, Inc. (Sanders TDI) to drive advancement of research in computational biomedicine. Through this collaboration, QCi will provide Sanders TDI with access to its quantum computation technology and hardware, specifically with its Dirac-3 Entropy Quantum Computing Machine, to support the Institute's experimental work.

Sanders TDI is a non-profit drug discovery institute based in New York City, composed of Kettering Cancer Center, The Rockefeller University, and Memorial Sloan Weill Cornell Medicine. The Institute's mission is to advance their groundbreaking biological discoveries to preclinical studies, focusing on the relevance of these findings for blocking disease initiation and progression. In addition, Sanders TDI provides industrial-scale technical support for academic research and projects.

As part of the collaboration, QCi will offer Sanders TDI cloud-based access to its Dirac-3 systems, which operate at room temperature and low power and are designed to solve complex optimization problems.

"We are truly excited to be a part of this strategic collaboration with Sanders TDI and to have our Dirac-3 systems support their efforts in rapidly assessing the efficacy of targeted therapeutics in treating human diseases," stated Dr. William McGann, Chief Executive Officer (CEO) of QCi. "This partnership exemplifies how QCi's quantum machines can provide powerful insights and useful analyses today. It aligns perfectly with our mission to make quantum machines accessible and affordable and is one of the many real-world applications where the power of quantum computing is being demonstrated and put into practice by QCi."

The collaboration will focus on advancing Sanders TDI's computational chemistry research by leveraging quantum technologies, including quantum analog computers, for proof of concept calculations in biomolecular modeling. Recognizing the diverse set of potential use cases in this field, QCi will work closely with Sanders TDI to explore a variety of quantum-enabled applications, with the goal of identifying the most promising use cases for its Dirac systems.

To learn more about how QCi is driving the future of accessible and affordable photonic technology or to explore collaboration opportunities, please visit the QCi webpage.

About Quantum Computing Inc.

Quantum Computing Inc. (Nasdaq: QUBT) is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. QCi's products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer unique capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.

For investor relations inquiries, contact John Nesbett at qci@imsinvestorrelations.com, and for public relations inquiries, contact Jessica Tocco at jessica.tocco@a10associates.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forecasts, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief, or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including the development of biomedical quantum applications, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/quantum-computing-inc-announces-collaboration-with-sanders-tri-institutional-therapeutics-discovery-institute-to-support-research-using-dirac-3-systems-302351488.html

SOURCE Quantum Computing Inc.

FAQ

What is the purpose of QUBT's collaboration with Sanders TDI?

The collaboration aims to advance computational biomedicine research by providing Sanders TDI access to QCi's Dirac-3 quantum computing technology for experimental work and computational chemistry research.

How will Sanders TDI access QUBT's Dirac-3 systems?

Sanders TDI will have cloud-based access to QCi's Dirac-3 systems, which operate at room temperature and low power.

What institutions are part of Sanders TDI collaborating with QUBT?

Sanders TDI comprises Kettering Cancer Center, The Rockefeller University, and Memorial Sloan Weill Cornell Medicine.

What specific applications will QUBT's Dirac-3 systems be used for at Sanders TDI?

The Dirac-3 systems will be used for computational chemistry research, biomolecular modeling, and proof of concept calculations in therapeutic research.

What are the technical advantages of QUBT's Dirac-3 systems mentioned in the collaboration?

The Dirac-3 systems operate at room temperature and low power, and are designed to solve complex optimization problems while being accessible and affordable.